Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Stem Cell-Based Cerebral Organoids Enable in Vitro Study of Human Brain Development and Microcephaly

By BiotechDaily International staff writers
Posted on 09 Sep 2013
Image: Comparison of the organoid (right) to the developing brain (left, section of a mouse brain) (Photo courtesy of the Institute of Molecular Biotechnology of the Austrian Academy of Sciences).
Image: Comparison of the organoid (right) to the developing brain (left, section of a mouse brain) (Photo courtesy of the Institute of Molecular Biotechnology of the Austrian Academy of Sciences).
Austrian researchers have used advanced stem cell technology to grow cultures of cerebral organoids, or "mini-brains," which enable the in vitro study of human neuronal disorders.

The complexity of the human brain has made it difficult to study many brain disorders in model organisms, highlighting the need for an in vitro model of human brain development. Investigators at the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (Vienna) have developed a human pluripotent stem cell-derived three-dimensional organoid culture system, termed cerebral organoids, which develop various discrete, although interdependent, brain regions. These include a cerebral cortex containing progenitor populations that organize and produce mature cortical neuron subtypes.

The investigators reported in the August 28, 2013, online edition of the journal Nature that after 15–20 days of culture growth cerebral organoids formed that consisted of continuous tissue (neuroepithelia) surrounding a fluid-filled cavity that was reminiscent of a cerebral ventricle. After 20–30 days, defined brain regions, including a cerebral cortex, retina, meninges, as well as choroid plexus, developed. After two months, the mini-brains reached a maximum size, but they could survive indefinitely (currently up to 10 months) in a spinning bioreactor. Further growth, however, was not achieved, most likely due to the lack of a circulation system and hence a lack of nutrients and oxygen at the core of the mini-brains

Cerebral organoids were shown to recapitulate features of human cortical development, namely characteristic progenitor zone organization with abundant outer radial glial stem cells. The investigators used RNA interference and patient-specific induced pluripotent stem cells to model microcephaly, a disorder that has been difficult to recapitulate in mice. They demonstrated premature neuronal differentiation in patient organoids, a defect that could help to explain the disease phenotype.

Senior author Dr. Jürgen Knoblich, deputy scientific director of the Institute of Molecular Biotechnology of the Austrian Academy of Sciences, said, "We modified an established approach to generate so-called neuroectoderm, a cell layer from which the nervous system derives. Fragments of this tissue were then maintained in a 3D-culture and embedded in droplets of a specific gel that provided a scaffold for complex tissue growth. In order to enhance nutrient absorption, we later transferred the gel droplets to a spinning bioreactor. Within three to four weeks defined brain regions were formed."

Related Links:
Institute of Molecular Biotechnology of the Austrian Academy of Sciences



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.